DMTTF: AI 评分 44/100 — AI 分析 (4月 2026)

Small Pharma Inc. is a biotechnology company focused on developing short-acting psychedelics for mental health conditions. Their lead clinical program involves N,N-dimethyltryptamine (DMT) assisted therapy for major depressive disorder.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Small Pharma Inc., a UK-based biotechnology firm, specializes in developing psychedelic-assisted therapies for mental health, with a focus on short-acting DMT treatments. Their lead program targets major depressive disorder, positioning them in the emerging market for innovative mental health solutions, but faces regulatory and clinical trial risks.

DMTTF是做什么的？

Small Pharma Inc. was founded in 2015 with the goal of pioneering short-acting psychedelic therapies for mental health disorders. The company's primary focus is on developing treatments using N,N-dimethyltryptamine (DMT), a potent psychedelic compound, in conjunction with psychotherapy. Their lead clinical program, SPL026, involves DMT-assisted therapy for major depressive disorder and is currently in Phase IIA clinical trials. Beyond SPL026, Small Pharma is also developing a pipeline of preclinical programs, including SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801, an oral formulation of 6-hydroxynorketamine. These programs aim to address various aspects of psychedelic therapy, such as duration of effect and route of administration. The company is headquartered in London, United Kingdom, and operates within the rapidly evolving landscape of psychedelic medicine, seeking to provide innovative solutions for unmet needs in mental healthcare. Small Pharma's strategy involves rigorous scientific research, clinical trials, and strategic partnerships to advance its pipeline and bring novel therapies to market.

DMTTF的投资论点是什么？

Small Pharma Inc. presents a high-risk, high-reward investment opportunity within the burgeoning psychedelic medicine sector. The company's focus on short-acting DMT therapies offers potential advantages in terms of patient convenience and therapeutic control. The Phase IIA clinical trial for SPL026 in major depressive disorder is a key value driver; positive results could significantly increase the company's valuation. However, the company's small market capitalization ($0.04B) and negative P/E ratio (-2.15) reflect the inherent risks associated with early-stage biotechnology companies. Successful navigation of regulatory hurdles and demonstration of clinical efficacy are critical for Small Pharma's long-term success.

DMTTF在哪个行业运营？

Small Pharma Inc. operates within the rapidly expanding psychedelic medicine industry, which is gaining increasing attention for its potential to treat mental health disorders. The market is driven by a growing unmet need for effective treatments for conditions like depression, anxiety, and PTSD. Companies like Small Pharma are pioneering the development of psychedelic-assisted therapies, facing both regulatory hurdles and significant market opportunities. The competitive landscape includes other biotechnology firms exploring various psychedelic compounds and therapeutic approaches, creating a dynamic and evolving market environment.

Biotechnology

Healthcare

DMTTF有哪些增长机遇？

Advancement of SPL026 through Clinical Trials: Successful completion of Phase IIA trials for SPL026 and progression to Phase III represents a significant growth opportunity. Positive clinical data could lead to regulatory approval and commercialization, addressing a substantial market for major depressive disorder treatments. The timeline for Phase III trials and potential market entry is estimated at 3-5 years, with a potential market size in the billions of dollars.
Expansion of Preclinical Pipeline: The development of SPL028, SPL029, and SPL801 offers opportunities to diversify Small Pharma's product portfolio and address different aspects of psychedelic therapy. These preclinical programs could lead to novel treatments with improved efficacy, duration of action, or routes of administration. The timeline for these programs to reach clinical trials is estimated at 2-4 years.
Strategic Partnerships and Collaborations: Forming partnerships with pharmaceutical companies, research institutions, or mental health clinics could accelerate the development and commercialization of Small Pharma's therapies. Collaborations can provide access to funding, expertise, and distribution channels, enhancing the company's competitive position. The potential impact of strategic partnerships is immediate and ongoing.
Geographic Expansion: Expanding operations beyond the United Kingdom to other regions with favorable regulatory environments for psychedelic medicine, such as North America and Europe, represents a growth opportunity. Geographic expansion could increase the company's market reach and revenue potential. The timeline for geographic expansion is estimated at 1-3 years.
Intellectual Property Protection: Securing and maintaining strong intellectual property protection for its psychedelic compounds and therapeutic methods is crucial for Small Pharma's long-term growth. Patents provide exclusivity and prevent competitors from replicating the company's innovations, creating a competitive advantage. The ongoing effort to strengthen and defend its IP portfolio is a continuous growth driver.

Market capitalization of $0.04 billion indicates a small-cap company with potential for high growth but also higher risk.
Negative P/E ratio of -2.15 reflects the company's current lack of profitability, common for biotechnology firms in the development stage.
Beta of 0.85 suggests the stock is less volatile than the overall market.
Lead clinical program, SPL026, is in Phase IIA trials, representing a key milestone in the drug development process.
Focus on short-acting DMT therapies differentiates Small Pharma from competitors developing longer-acting psychedelic treatments.

DMTTF提供哪些产品和服务？

Develop short-acting psychedelic therapies for mental health conditions.
Conduct clinical trials to evaluate the safety and efficacy of DMT-assisted therapy.
Research and develop novel psychedelic compounds and formulations.
Seek regulatory approval for their therapies from health authorities.
Commercialize approved therapies through partnerships or direct sales.
Explore new applications of psychedelic medicine in mental healthcare.

DMTTF如何赚钱？

Develop and patent novel psychedelic compounds and therapeutic methods.
Conduct clinical trials to demonstrate safety and efficacy.
Seek regulatory approval from health authorities.
Commercialize approved therapies through partnerships or direct sales.

Patients suffering from mental health disorders, such as major depressive disorder.
Mental health professionals who administer psychedelic-assisted therapy.
Healthcare providers who prescribe or recommend Small Pharma's therapies.
Pharmaceutical companies that may partner with Small Pharma for commercialization.

Intellectual property protection for novel psychedelic compounds and therapeutic methods.
Clinical data demonstrating the safety and efficacy of their therapies.
Strategic partnerships with pharmaceutical companies and research institutions.
First-mover advantage in the emerging market for short-acting DMT therapies.

什么因素可能推动DMTTF股价上涨？

Upcoming: Release of Phase IIA clinical trial results for SPL026 in major depressive disorder (timeline: within the next 6-12 months).
Upcoming: Initiation of Phase III clinical trials for SPL026, contingent on positive Phase IIA results (timeline: potentially within 1-2 years).
Ongoing: Development and advancement of preclinical programs, including SPL028, SPL029, and SPL801.
Ongoing: Potential for strategic partnerships with pharmaceutical companies or research institutions.
Ongoing: Regulatory developments and changes in the legal status of psychedelic therapies.

DMTTF的主要风险是什么？

Potential: Failure to achieve positive results in clinical trials for SPL026 or other pipeline programs.
Potential: Regulatory setbacks and delays in the approval process for psychedelic therapies.
Potential: Competition from other biotechnology companies developing psychedelic therapies.
Ongoing: Negative public perception of psychedelic drugs and potential for social stigma.
Ongoing: Limited financial resources and potential need for additional funding.

DMTTF的核心优势是什么？

Focus on short-acting DMT therapies offers potential advantages in terms of patient convenience and therapeutic control.
Lead clinical program, SPL026, is in Phase IIA trials, representing a key milestone.
Strong intellectual property portfolio protecting novel psychedelic compounds and therapeutic methods.
Experienced management team with expertise in drug development and commercialization.

DMTTF的劣势是什么？

Small market capitalization and limited financial resources.
Reliance on a single lead clinical program, SPL026.
High regulatory hurdles and uncertainty surrounding the approval of psychedelic therapies.
Limited commercialization experience.

DMTTF有哪些机遇？

Growing market for psychedelic medicine and increasing acceptance of psychedelic therapies.
Potential for strategic partnerships with pharmaceutical companies and research institutions.
Expansion of preclinical pipeline to address different aspects of psychedelic therapy.
Geographic expansion to regions with favorable regulatory environments.

DMTTF面临哪些威胁？

Competition from other biotechnology companies developing psychedelic therapies.
Regulatory setbacks and delays in the approval process.
Negative public perception of psychedelic drugs.
Patent challenges and intellectual property disputes.

DMTTF的竞争对手是谁？

Algernon Pharmaceuticals Inc. — Focuses on repurposing existing drugs for new indications. — (ACOGF)
COMPASS Pathways plc — Developing psilocybin therapy for treatment-resistant depression. — (CSWYY)
Enzolytics, Inc. — Focuses on anti-viral therapeutics. — (ENZB)
IGX Group, Inc. — Develops cannabinoid-based therapies. — (IGXT)
IMMPower Corp. — Focuses on nutraceuticals and wellness products. — (IMMPF)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: George Tziras
Headquarters: London, GB
Founded: 2021

AI Insight

AI analysis pending for DMTTF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Small Pharma Inc. do?

Small Pharma Inc. is a biotechnology company focused on developing short-acting psychedelic-assisted therapies for mental health conditions, primarily major depressive disorder. Their lead clinical program, SPL026, utilizes N,N-dimethyltryptamine (DMT) in conjunction with psychotherapy. The company aims to provide innovative and effective treatments for mental health disorders by leveraging the unique properties of DMT and other psychedelic compounds. Their business model involves research, clinical trials, regulatory approval, and eventual commercialization of these therapies.

What do analysts say about DMTTF stock?

As of March 18, 2026, formal analyst coverage of DMTTF is limited due to its small market capitalization and OTC listing. However, the general sentiment surrounding the psychedelic medicine sector is positive, with increasing recognition of the potential of psychedelic therapies to address unmet needs in mental healthcare. Investors should conduct their own due diligence and consider the inherent risks associated with early-stage biotechnology companies before investing in DMTTF. Key valuation metrics and growth considerations include the progress of SPL026 through clinical trials and the company's ability to secure regulatory approval.

What are the main risks for DMTTF?

The main risks for Small Pharma Inc. include the inherent uncertainties associated with drug development, such as the potential for clinical trial failures or regulatory setbacks. The company also faces competition from other biotechnology companies developing psychedelic therapies. Negative public perception of psychedelic drugs and potential for social stigma could also hinder the adoption of their therapies. Additionally, Small Pharma's limited financial resources and reliance on a single lead clinical program represent significant risks for investors.